跳至主要内容
临床试验/CTRI/2021/10/037442
CTRI/2021/10/037442已完成3 期

A Randomized double blind placebo controlled trial to determine the therapeutic efficacy of AYUSH medicine NOQ19 in treatment of symptomatic COVID-19 patients along with standard allopathic treatment

Sriveda Sattva Pvt Ltd0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Symptomatic COVID-19 Infection with or without comorbidities.
  • Willingness to participate in the Study
  • Indian Nationals

排除标准

  • Age less than 18 years and age above 65 years.
  • Patients not willing to participate in the study.
  • Pregnancy and Lactation

研究者

发起方
Sriveda Sattva Pvt Ltd

相似试验